Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia.
about
Rituximab, ofatumumab and other monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemiaOfatumumab: a novel monoclonal anti-CD20 antibodyThe emerging role of ofatumumab in the treatment of chronic lymphocytic leukemiaThe role of idelalisib in the treatment of relapsed and refractory chronic lymphocytic leukemiaNew developments in the management of chronic lymphocytic leukemia: role of ofatumumabObinutuzumab: A Novel Anti-CD20 Monoclonal Antibody for Chronic Lymphocytic LeukemiaOfatumumabProfile of obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemiaNovel Targeted Agents in Hodgkin and Non-Hodgkin Lymphoma TherapyClinical utility and patient considerations in the use of ofatumumab in chronic lymphocytic leukemiaImmune Modulation in Hematologic MalignanciesClinical implications of the molecular genetics of chronic lymphocytic leukemiaTrial Watch: Tumor-targeting monoclonal antibodies in cancer therapyTargeted therapies in CLL: mechanisms of resistance and strategies for managementNew antibody approaches to lymphoma therapyThe biology behind B-cell lymphoma 2 as a target in chronic lymphocytic leukemiaChronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatmentThe biology behind PI3K inhibition in chronic lymphocytic leukaemiaIdelalisib and rituximab in relapsed chronic lymphocytic leukemiaNovel CD20 monoclonal antibodies for lymphoma therapyTargeting BTK with ibrutinib in relapsed chronic lymphocytic leukemiaIbrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy.Complement dependent cytotoxicity in chronic lymphocytic leukemia: ofatumumab enhances alemtuzumab complement dependent cytotoxicity and reveals cells resistant to activated complement.Induced resistance to ofatumumab-mediated cell clearance mechanisms, including complement-dependent cytotoxicity, in chronic lymphocytic leukemia.Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies.The value of rituximab for the treatment of fludarabine-refractory chronic lymphocytic leukemia: a systematic review and qualitative analysis of the literature.Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia.Phase II study of cenersen, an antisense inhibitor of p53, in combination with fludarabine, cyclophosphamide and rituximab for high-risk chronic lymphocytic leukemia.Utility elicitation study in the UK general public for late-stage chronic lymphocytic leukaemia.The combination of rituximab, bendamustine, and cytarabine for heavily pretreated relapsed/refractory cytogenetically high-risk patients with chronic lymphocytic leukemia.The use of monoclonal antibodies in the treatment of autoimmune complications of chronic lymphocytic leukemia.A multicentre, phase II trial of ofatumumab monotherapy in relapsed/progressive diffuse large B-cell lymphoma.Sequential ofatumumab and lenalidomide for the treatment of relapsed and refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLLOfatumumab in poor-prognosis chronic lymphocytic leukemia: a phase IV, non-interventional, observational study from the European Research Initiative on Chronic Lymphocytic Leukemia.Safety and efficacy of Ofatumumab in chronic lymphocytic leukemia: a systematic review and meta-analysis.The clinical development of obinutuzumab for the treatment of follicular lymphoma.Next generation of antibody therapy for cancer.Immunotherapy in hematologic malignancies: past, present, and future.A phase 1/2 trial of ublituximab, a novel anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab.
P2860
Q24203027-A9774E67-CCD1-4536-9C70-F57919B8F58EQ24604065-5967815C-03F4-4D4D-BD08-7EC12535A3F8Q24617708-19E27E7E-9053-4BFC-BCEE-722A8402C501Q26751006-C611D461-13C1-428E-82ED-78CABDA8EDD6Q26768396-297E4740-4230-4F4C-B936-45B1B8370E48Q26771940-087A53C8-6E8D-4191-A74A-9352AE919DB9Q26773260-C6F5AD47-59F6-411B-8EE4-08469CC7CCF7Q26781163-4309F4F3-D829-458C-BDCD-3F05CAE28AC5Q26782270-22CAFD53-E823-4395-806F-9643BD0C44FFQ26783600-8773F04F-AD51-498E-903E-AE3EC8954C05Q26796307-C39CB42B-5C6D-4A40-93E8-45EED64383E0Q26830955-99AAEED8-6E7A-48E5-8EE6-8388465B8688Q26993238-783493F0-4CAE-4A97-95C0-091ABB82C296Q27002528-213FFEBD-9331-4831-BDA6-8FA0AF4F63ABQ27022373-743F95CA-1EC2-46D3-A5E4-1AE0BC53BEE3Q28075683-194E26A9-8976-4CA0-A434-6121A4822066Q28082086-C675596D-7D34-4E09-A300-0F5BA8B94336Q28083266-CE89D8CC-A391-4F43-9D57-5C86EC399F30Q28306347-9F7359F4-1418-4D69-8331-13219B110047Q28390112-608D5F2A-F169-4F84-88A0-A5239D8E19A6Q29620690-85DC0E9B-3556-4189-92D7-78D30173B0C2Q30303054-EA06A6DD-2E6E-4ECD-8D76-94A98ADA6603Q30356145-03A6CB29-E099-47DB-B178-86AF689F3E83Q30405847-3FEBE45C-F592-47BD-B2F2-5E2C68ABBBE5Q30500362-DB86D3D6-D06E-47C9-BE7A-0A1B666570BFQ31033615-4C7E88DB-138D-49A0-9028-0636B1BDC94FQ33394947-DEEB1148-7285-41FE-99DA-77C01F6BC6ABQ33396594-36647E86-507F-4DBC-88AE-0E8878F7E333Q33403077-64BA69B4-5AC2-436F-AA82-6D9434C488A3Q33406164-5975BB05-E565-4EE8-A9DC-0C03EA46113CQ33407700-1E3EB2D5-19CF-4BAB-B1DB-B41F4861671CQ33410306-E884760D-0186-4176-9CF1-F3298130442EQ33417117-9EA44F34-698B-47D7-909E-1BDF4E2A0F6FQ33418091-973BA7CD-4AF6-4FFC-A9F7-102BE530A159Q33419843-5B43CF60-69F2-4AA8-9AED-DF92648A14DEQ33442438-8A3836DE-81D2-40A3-AF4F-C24F347C1C32Q33565265-DDE8A8EB-483C-452E-B5F2-A0077F867EFAQ33579636-59F19B68-6CC7-4459-B698-CE92DE1354E2Q33593865-B38E8A43-9997-475D-B7F1-3762E0322F26Q33626106-575876D8-BE03-4875-8539-8D0F2CEF4040
P2860
Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մարտին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Ofatumumab as single-agent CD2 ...... chronic lymphocytic leukemia.
@ast
Ofatumumab as single-agent CD2 ...... chronic lymphocytic leukemia.
@en
Ofatumumab as single-agent CD2 ...... chronic lymphocytic leukemia.
@en-gb
Ofatumumab as single-agent CD2 ...... chronic lymphocytic leukemia.
@nl
type
label
Ofatumumab as single-agent CD2 ...... chronic lymphocytic leukemia.
@ast
Ofatumumab as single-agent CD2 ...... chronic lymphocytic leukemia.
@en
Ofatumumab as single-agent CD2 ...... chronic lymphocytic leukemia.
@en-gb
Ofatumumab as single-agent CD2 ...... chronic lymphocytic leukemia.
@nl
prefLabel
Ofatumumab as single-agent CD2 ...... chronic lymphocytic leukemia.
@ast
Ofatumumab as single-agent CD2 ...... chronic lymphocytic leukemia.
@en
Ofatumumab as single-agent CD2 ...... chronic lymphocytic leukemia.
@en-gb
Ofatumumab as single-agent CD2 ...... chronic lymphocytic leukemia.
@nl
P2093
P2860
P50
P921
P356
P1476
Ofatumumab as single-agent CD2 ...... chronic lymphocytic leukemia.
@en
P2093
Anders Osterborg
Andrzej Hellmann
Cathy D Williams
Charlotte A Russell
Geoffrey Chan
Hx-CD20-406 Study Investigators
Jirí Mayer
Joris Wilms
Magdalena Piotrowska
Martin J S Dyer
P2860
P304
P356
10.1200/JCO.2009.25.3187
P407
P577
2010-03-01T00:00:00Z